Ideaya Biosciences (IDYA)
NASDAQ:IDYA
Want to see IDYA full AI Analyst Report?
IDYA Stock Chart & Stats
$33.91
$0.01(0.06%)
At close: 4:00 PM EST
$33.91
$0.01(0.06%)
Day’s Range― - ―
52-Week Range$20.50 - $39.28
Previous CloseN/A
Volume96.34K
Average Volume (3M)1.01M
Market Cap
$2.76B
Enterprise Value$2.46B
Total Cash (Recent Filing)$671.20M
Total Debt (Recent Filing)$28.60M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 11, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding95,083,145
10 Day Avg. Volume1,464,912
30 Day Avg. Volume1,012,235
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue10.92
Enterprise Value/Gross Profit36.77
Enterprise Value/Ebitda-18.16
Forecast
1Y Price Target
$54.00Price Target Upside59.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.34
Revenue Forecast (FY)$34.69M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageVery low leverage and ~ $1.03B in assets give IDEAYA durable financial flexibility to fund R&D and sponsor mid-stage trials without immediate refinancing risk. This reduces solvency pressure during clinical readouts and supports strategic partnerships and program advancement over months.
Material Revenue Growth With High Gross MarginsSubstantially higher, high-margin revenue (likely collaboration/other biotech revenue) improves operating leverage and can sustainably offset part of R&D spend. Durable high gross margins mean incremental revenue largely drops to cover fixed R&D and SG&A, strengthening mid-term cash resilience.
Clinical/regulatory Progress And Strategic PartnershipsRobust registrational darovasertib data plus FDA RTOR and collaborations with Roche and AstraZeneca materially de-risk key programs and validate IDEAYA's precision oncology strategy. These durable developments expand commercialization optionality and attract partner resources for further development.
Bears Say
Persistent Negative Cash FlowAlthough burn has improved significantly, ongoing negative operating and free cash flow requires sustained financing or meaningful operating improvements. Continued negative cash generation constrains optionality and may force program prioritization or further capital raises over the medium term.
Large Ongoing Operating And Net LossesDeep negative operating and net margins reflect that R&D and development costs still outpace revenue. Until revenues scale or costs are curtailed, sustained losses will limit ability to deliver positive cash flow and could pressure strategic choices and partner negotiations over the next several quarters.
Equity Capital Raises Imply Dilution RiskA large equity raise meaningfully bolsters runway but dilutes existing shareholders and signals reliance on public markets for funding. Recurring or large future raises remain possible until profitability or cash-positive operations are achieved, a structural governance and ownership risk.
IDEAYA Biosciences News
IDYA FAQ
What was Ideaya Biosciences’s price range in the past 12 months?
Ideaya Biosciences lowest stock price was $20.50 and its highest was $39.28 in the past 12 months.
What is Ideaya Biosciences’s market cap?
Ideaya Biosciences’s market cap is $2.76B.
When is Ideaya Biosciences’s upcoming earnings report date?
Ideaya Biosciences’s upcoming earnings report date is Aug 11, 2026 which is in 57 days.
How were Ideaya Biosciences’s earnings last quarter?
Ideaya Biosciences released its earnings results on May 05, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.989 by -$0.121.
Is Ideaya Biosciences overvalued?
According to Wall Street analysts Ideaya Biosciences’s price is currently Undervalued.
Does Ideaya Biosciences pay dividends?
Ideaya Biosciences does not currently pay dividends.
What is Ideaya Biosciences’s EPS estimate?
Ideaya Biosciences’s EPS estimate is -1.07.
How many shares outstanding does Ideaya Biosciences have?
Ideaya Biosciences has 95,083,145 shares outstanding.
What happened to Ideaya Biosciences’s price movement after its last earnings report?
Ideaya Biosciences reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.989. Following the earnings report the stock price went down -0.346%.
Which hedge fund is a major shareholder of Ideaya Biosciences?
Currently, no hedge funds are holding shares in IDYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEAYA Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (59.25% Upside)
$54.00 (59.25% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 328.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 43%
Bearish news 43%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.07%
12-Months-Change
Fundamentals
Return on Equity
-13.96%
Trailing 12-Months
Asset Growth
-6.39%
Trailing 12-Months
Company Description
Ideaya Biosciences
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
IDYA Stock 12 Month Forecast
Average Price Target
$54.00
▲(59.25% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Celcuity
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
0.82% Insiders
29.37% Mutual Funds
32.55% Other Institutional Investors
23.37% Public Companies and
Individual Investors